Borderline Over Tümörler
Özet
Overin borderline tümörleri, invaziv over tümörlerine göre daha genç yaşta ve daha erken evrelerde tespit edilebilen, primer tedavisi cerrahi olan tümörlerdir. Primer tedavi sonrası takipte temel unsur fizik muayene ile takiptir. Her ne kadar tanıda hastaların büyük kısmında Ca-125 yüksekliği görülmese de tanıda yükseklik tespit edilmiş hastaların takibine bu tümör belirteç eklenebilir. Genç yaşta tanı alan hastalara fertilite koruyucu cerrahi yapıldıysa abdominopelvik ultrasonografik takip de önerilmektedir. İleri görüntüleme yöntemleri takip parametlerinde ek bulgu varsa yapılması değerlendirilmelidir. OBT tanısı almış hastaların takibinde yaşa uygun olarak sekonder malignite taramalarının da yapılması akılda tutulmalıdır.
Borderline tumors of the ovary (BOT) are tumors that can be detected at a younger age and earlier stages than invasive ovarian tumors. The primary treatment modality of BOT is surgery. The essential element in follow-up after primary treatment is physical examination. Although Ca-125 elevation is not observed in most patients at diagnosis, this tumor marker can be added to patients' follow-up if elevation is detected at diagnosis. If fertility-sparing surgery has been performed in patients diagnosed at a young age, abdominopelvic ultrasonographic follow-up is also recommended. Advanced imaging methods should be considered if there are additional findings in the follow-up parameters. In the follow-up of patients diagnosed with OBT, it should be kept in mind that secondary malignancy screening should be performed according to the patient’s age.
Referanslar
Seong SJ, Kim DH, Kim MK, Song T, et al. Controversies in borderline ovarian tumors. Journal of Gynecological Oncology. 2015; 26:343–349. doi: 10.3802/jgo.2015.26.4.343.
Della Corte L, Mercorio A, Serafino P, et al. The challenging management of borderline ovarian tumors (BOTs) in women of childbearing age. Frontiers in Surgery. Frontiers Media S.A.; 2022. doi: 10.3389/fsurg.2022.973034
Abascal-Saiz A, Sotillo-Mallo L, De Santiago J, et al. Management of borderline ovarian tumours: A comprehensive review of the literature. Ecancermedicalscience. 2014;8. doi: 10.3332/ecancer.2014.403.
Nakashima N, Nagasaka T, Oiwa N, et al. Ovarian Epithelial Tumors of Borderline Malignancy in Japan. Gynecologic Oncology. 1990; 38:90-98.
du Bois A, Trillsch F, Mahner S, et al. Management of borderline ovarian tumors. Annals of Oncology. 2016;27: i20–i22. doi: 10.1093/annonc/mdw090.
Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecologic Oncology. 2002; 86:34–37. doi: 10.1006/gyno.2002.6711.
NCCN. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 3.2024. [Online] https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf [Accessed: 06th December 2024].
Ledermann JA, Matias-Guiu X, Amant F, et al. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Annals of Oncology. Elsevier Ltd; 2024. p. 248–266. doi: 10.1016/j.annonc.2023.11.015
Uzan C, Kane A, Rey A, et al. How to follow up advanced-stage borderline tumours? Mode of diagnosis of recurrence in a large series stage II-III serous borderline tumours of the ovary. Annals of Oncology. 2011; 22:631–635. doi: 10.1093/annonc/mdq414.
Fischerova D, Zikan M, Dundr P, et al. Diagnosis, Treatment, and Follow-Up of Borderline Ovarian Tumors. Oncologist. 2012; 17:1515–1533. doi: 10.1634/theoncologist.2012-0139.
Bouchardy C, Fernandez S, Merglen A, et al. Increased risk of second cancer among patients with ovarian borderline tumors. Gynecologic Oncology. 2008; 109:210–214. doi: 10.1016/j.ygyno.2008.01.032.
Lazarou A, Fotopoulou C, Coumbos A, et al. Long-term Follow-up of Borderline Ovarian Tumors Clinical Outcome and Prognostic Factors. Anticancer Research. 2014; 34: 6725-6730.
